The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells
Open accessAbstract
The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been attributed to supraphysiological signaling through CARs. Second- and later-generation CARs simultaneously transmit costimulatory signals with CD3ζ signals upon ligation, but may lead to severe adverse effects owing to the recognition of minimal Ag expression outside the target tumor. Currently, the threshold target Ag density for CAR-T cell lysis and further activation, including cytokine production, has not yet been investigated in detail. Therefore, we determined the threshold target Ag density required to induce CAR-T cell responses using novel anti-CD20 CAR-T cells with a CD28 intracellular domain and a CD20-transduced CEM cell model. The newly developed CD20CAR–T cells demonstrated Ag-specific lysis and cytokine secretion, which was a reasonable level as a second-generation CAR. For lytic activity, the threshold Ag density was determined to be ∼200 molecules per target cell, whereas the Ag density required for cytokine production of CAR-T cells was ∼10-fold higher, at a few thousand per target cell. CD20CAR–T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells. Despite the potential influence of the structure, localization, and binding affinity of the CAR/Ag, the threshold determined may be used for target Ag selection. An Ag density below the threshold may not result in adverse effects, whereas that above the threshold may be sufficient for practical effectiveness. CD20CAR–T cells also demonstrated significant lytic activity against CD20-downregulated tumor cells and may exhibit effectiveness for CD20-positive lymphoid malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Monoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T. M., Hassan, N. J., Gavarret, J., Bianchi, F. C., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 324
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275
Hiraga, J., Tomita, A., Sugimoto, T., Shimada, K., Ito, M., Nakamura, S., Kiyoi, H., Kinoshita, T., & Naoe, T. (2009) · Blood · doi:10.1182/blood-2008-08-175208 · Cited by 257
Self-citationvan Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A., & Ebeling, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0066 · Cited by 250
Self-citationFaroudi, M., Utzny, C., Salio, M., Cerundolo, V., Guiraud, M., Müller, S., & Valitutti, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2334336100 · Cited by 239
Design and Construction of 2A Peptide-Linked Multicistronic Vectors
Szymczak-Workman, A. L., Vignali, K. M., & Vignali, D. A. A. (2012) · Cold Spring Harbor Protocols · doi:10.1101/pdb.ip067876 · Cited by 232
Abramson, J. S., & Shipp, M. A. (2005) · Blood · doi:10.1182/blood-2005-02-0687 · Cited by 208
Terakura, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2012) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196
Self-citationDesign and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 170
Wierda, W. G., Padmanabhan, S., Chan, G. W., Gupta, I. V., Lisby, S., Österborg, A., & for the Hx-CD20-406 Study Investigators (2011) · Blood · doi:10.1182/blood-2011-04-348656 · Cited by 160
Oncogenic protein tyrosine kinases
M�nard, S., Casalini, P., Campiglio, M., Pupa, S. M., & Tagliabue, E. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4277-7 · Cited by 137
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136
Tang, Y., Lou, J., Alpaugh, R. K., Robinson, M. K., Marks, J. D., & Weiner, L. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2815 · Cited by 135
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
Jaglowski, S. M., Alinari, L., Lapalombella, R., Muthusamy, N., & Byrd, J. C. (2010) · Blood · doi:10.1182/blood-2010-04-001230 · Cited by 124
Purbhoo, M. A., Sutton, D. H., Brewer, J. E., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7308 · Cited by 97
Performance of calibration standards for antigen quantitation with flow cytometry
Lenkei, R., Gratama, J. W., Rothe, G., Schmitz, G., D'hautcourt, J., �rekrans, A., Mandy, F., & Marti, G. E. (1998) · Cytometry · doi:10.1002/(sici)1097-0320(19981001)33:2<188::aid-cyto13>3.0.co;2-q · Cited by 97
The predictive significance of CD20 expression in B-cell lymphomas
Prevodnik, V. K., Lavrenčak, J., Horvat, M., et al. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-33 · Cited by 83
Turatti, F., Figini, M., Balladore, E., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de5d90 · Cited by 77
Engineered T cells for anti-cancer therapy
Turtle, C. J., Hudecek, M., Jensen, M. C., & Riddell, S. R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.06.004 · Cited by 73
Johnson, N. A., Leach, S. R., Woolcock, B. W., deLeeuw, R. J., Bashashati, A., Sehn, L. H., Connors, J. M., Chhanabhai, M., Brooks-Wilson, A. R., & Gascoyne, R. D. (2009) · Haematologica · doi:10.3324/haematol.2008.001024 · Cited by 72
Tomita, A., Hiraga, J., Kiyoi, H., Ninomiya, M., Sugimoto, T., Ito, M., Kinoshita, T., & Naoe, T. (2007) · International Journal of Hematology · doi:10.1532/ijh97.07028 · Cited by 60
Self-citationDevelopment of novel humanized anti‐CD20 antibodies based on affinity constant and epitope
Uchiyama, S., Suzuki, Y., Otake, K., Yokoyama, M., Ohta, M., Aikawa, S., Komatsu, M., Sawada, T., Kagami, Y., Morishima, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01392.x · Cited by 46
Self-citationLessons learned from a highly-active CD22-specific chimeric antigen receptor
Long, A. H., Haso, W. M., & Orentas, R. J. (2013) · OncoImmunology · doi:10.4161/onci.23621 · Cited by 27
Sonoki, T., Li, Y., Miyanishi, S., Nakamine, H., Hanaoka, N., Matsuoka, H., Mori, I., & Nakakuma, H. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0295-4 · Cited by 15
Shimada, K., Tomita, A., Saito, S., & Kiyoi, H. (2014) · British Journal of Haematology · doi:10.1111/bjh.12857 · Cited by 7
Self-citation
Cited by
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Metadata
- Authors
- Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., Shimada, K., Tomita, A., Kiyoi, H., Nishida, T., Naoe, T., & Murata, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-01
- Volume
- 194
- Issue
- 3
- Pages
- 911-920
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1868169777
- Cited by
- 284
- References
- 43
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.